Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease | Zendy

Maartje I. Kester | Zendy; Charlotte E. Teunissen | Zendy; Daniel L. Crimmins | Zendy; Elizabeth Herries | Zendy; Jack H. Ladenson | Zendy; Philip Scheltens | Zendy; Wiesje M. van der Flier | Zendy; John C. Morris | Zendy; David M. Holtzman | Zendy; Anne M. Fagan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

Author(s) -

Maartje I. Kester,

Charlotte E. Teunissen,

Daniel L. Crimmins,

Elizabeth Herries,

Jack H. Ladenson,

Philip Scheltens,

Wiesje M. van der Flier,

John C. Morris,

David M. Holtzman,

Anne M. Fagan

Publication year - 2015

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2015.1867

Subject(s) - interquartile range , cerebrospinal fluid , neurogranin , medicine , biomarker , lumbar , cohort , memory clinic , dementia , lumbar puncture , alzheimer's disease , gastroenterology , disease , surgery , biology , biochemistry , protein kinase c , enzyme

Neurogranin (NGRN) seems to be a promising novel cerebrospinal fluid (CSF) biomarker for synaptic loss; however, clinical, and especially longitudinal, data are sparse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research